Antibody response to COVID-19 vaccine: research by Sapienza and Policlinico Umberto I General Hospital
The antibody response to COVID-19 vaccine is higher in women, younger people, non-smokers and people with no underlying conditions related to cardiovascular risks. The response is maintained even six months after the first dose. Sapienza University of Rome and Policlinico Umberto I General Hospital carried out the study
On October 19, the results of the antibody response study, 2 and 6 months after the second dose of Pfizer-Biontech vaccine in 2065 healthcare workers (age: 46+13 years; 63% women), were presented.
This important work", says Fabrizio d'Alba, Director General of Policlinico Umberto I General Hospital, "adds a significant piece to what Sapienza and the Policlinico are doing in support of public health as part of the COVID-19 national vaccination campaign".
Please click on the Italian version of this page for more information.
Wednesday, 20 October 2021